without clarity of strategy, this it looks like (from the article).
Precision wants to partner the cell therapy programs and pivot to the in vivo gene editing applications of its technology. The Imugene deal supports the plan by adding to Precision’s bank balance and wiping $20 million off its annual spending, changes that could extend the biotech’s cash runway to the third quarter of 2025, up from the first quarter of 2025 under the previous plan.
we paid to acquire $20m in costs and precision stops bleeding $20m.
love the headline comment too “punts early phase Car-t to imugene “.
should fill us with confidence.
again…. Need the strategic intent from LC and Hopper.
Media Thread, page-9874
-
- There are more pages in this discussion • 5,677 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $1.098M | 21.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 97 | 7481668 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 1703097 | 4 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |